Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
MaxCyte ( (MXCT) ) has issued an update.
MaxCyte announced the retirement of Art Mandell from its Board of Directors, effective December 31, 2024. Mandell, who served since 2006, played a significant role in the company’s growth, including its public offerings and pioneering work in cell and gene therapy. His departure sees Patrick Balthrop, Sr. appointed as the new Chairman of the Nominating and Corporate Governance Committee. MaxCyte continues to position itself as a leader in cell engineering, leveraging Mandell’s contributions to its strategic direction and industry achievements.
More about MaxCyte
MaxCyte, Inc. is a leading company in the cell engineering sector, providing platform technologies that facilitate the discovery, development, and commercialization of next-generation cell therapeutics. Their ExPERT™ platform, based on Flow Electroporation® technology, supports the expanding cell therapy market and includes a range of instruments, processing assemblies, and software protocols aimed at advancing cell-based medicine.
YTD Price Performance: -7.23%
Average Trading Volume: 48,536
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £342.8M
See more data about MXCT stock on TipRanks’ Stock Analysis page.
